Zhejiang Beta Pharma Forms JV with Amgen

Zhejiang Beta Pharma and Amgen will form a joint venture to commercialize Amgen's Vectibix ® (panitumumab) in China. Vectibix is a treatment for colorectal cancer. In addition to being experienced with targeted therapies, Zhejiang Beta also has a well-established China oncology sales network. The JV will be 51% owned by Zhejiang Beta, with Amgen holding the remainder. More details.... Stock Symbol: (NSDQ: AMGN) Share this with colleagues: // //